Join the 'Actinic Keratosis' group to help and get support from people like you. How it works
New Gel Treats Precancerous Skin Condition in Days: Study
Posted 14 Mar 2012 by Drugs.com
WEDNESDAY, March 14 – A newly approved gel appears effective in treating a condition called actinic keratosis, which is a common precursor to squamous cell skin cancer, a new study finds. Earlier topical treatments took weeks or even months to treat the condition, but the new product – Picato (ingenol mebutate) gel – can work in a matter of days, according to the report in the March 15 issue of the New England Journal of Medicine. "There are a number of agents available to treat precancerous skin lesions," said study author Dr. Mark Lebwohl, a professor and chairman of dermatology at Mount Sinai School of Medicine in New York City. "Most of the other ones are applied over a period of weeks to months and have a reaction that lasts for a long time, so it interferes with your life for a good period of time. This one is unique in that it is applied for only one to three days," he said. ... Read more
Related support groups: Actinic Keratosis, Squamous Cell Carcinoma, Picato
FDA Approves Picato (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
Posted 25 Jan 2012 by Drugs.com
PARSIPPANY, N.J., January 25, 2012, 2012 /PRNewswire/ – Leo Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK). AK is a precancerous condition caused by cumulative sun exposure that has the potential to progress to squamous cell carcinoma (SCC), the second most common type of skin cancer.[1],[2] Picato 0.015% gel is used once daily on the face and scalp for three consecutive days, and Picato 0.05% gel is used once daily on the trunk and extremities for two consecutive days.[3] Picato gel is the first and only topical AK therapy that can be used for as little as two or three days. According to the American Academy of Dermatology (AAD), 1 in 5 Americans will develop skin cancer in the course of their lifetime.[4] Studies show that about 65 percent of squamous ... Read more
Related support groups: Actinic Keratosis
FDA Approves Zyclara (imiquimod) Cream, 2.5% for the Treatment of Actinic Keratoses
Posted 29 Jul 2011 by Drugs.com
BRISTOL, Tenn.--(BUSINESS WIRE)--Jul 18, 2011 - Graceway Pharmaceuticals, LLC (Graceway) announced today that the Food and Drug Administration (FDA) has approved Zyclara Cream, 2.5% for the treatment of actinic keratoses, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses (AK). The new formulation may be used on the full face or balding scalp in a convenient 6-week dosing cycle. "The addition of a 2.5% formulation of Zyclara Cream will provide healthcare practitioners greater flexibility when prescribing imiquimod therapy for patients with actinic keratoses," said Dr. Darrell S. Rigel, a clinical professor of dermatology at New York University Medical Center and a former president of the American Academy of Dermatology. "The lower concentration offers greater tolerability while maintaining the efficacy that has long ... Read more
Related support groups: Zyclara, Actinic Keratosis, Imiquimod
FDA Approves Zyclara (imiquimod) Cream, 3.75% for the Treatment of Actinic Keratoses
Posted 29 Mar 2010 by Drugs.com
BRISTOL, Tenn., March 26 /PRNewswire/ – Graceway Pharmaceuticals announced today that the Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Zyclara, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses (AK). The new treatment can be used on large areas of skin, including the full face or balding scalp on a convenient, 6-week dosing cycle. Zyclara shares the same active ingredient as Aldara (imiquimod) Cream, 5% and while both topicals are FDA-approved for the treatment of AK, there are notable differences between the two. Zyclara is indicated for daily use on an accelerated 6-week dosing cycle comprised of two weeks of daily treatment with Zyclara, two weeks of non-treatment, followed by two weeks of daily treatment with Zyclara. Aldara is not approved for daily use and its approved ... Read more
Related support groups: Actinic Keratosis, Imiquimod
Chemo Drug May Help Sun-Damaged Skin
Posted 15 Jun 2009 by Drugs.com
MONDAY, June 15 – Applying the chemotherapy drug fluorouracil to skin might help improve the appearance of sun-damaged areas and reduce potentially precancerous patches, according to a small, new study. Fluorouracil is used to treat cancers of the colon, head and neck, pancreas and other organs. Changes in skin appearance have been noted in people undergoing treatment with systemic fluorouracil, and this led to the development of a skin cream that contains the cancer drug. The new study included 21 healthy volunteers with sun-damaged skin and actinic keratoses – skin lesions that could develop into skin cancer – on their faces. The participants applied 5 percent fluorouracil cream to their faces twice daily for two weeks. The researchers said that the number of actinic keratoses declined from an average of 11.6 lesions per person to an average of 1.5 lesions. There were also ... Read more
Related support groups: Carac, Actinic Keratosis
Ask a Question
Further Information
Related Condition Support Groups
Related Drug Support Groups
Carac, Efudex, Aldara, Zyclara, Fluoroplex, Santyl, imiquimod, collagenase, Levulan Kerastick, view more... Picato, Solaraze, ingenol mebutate, Collagenase Santyl, Metvixia, methyl aminolevulinate, Actinex, aminolevulinic acid, masoprocol, Efudex Occlusion Pack